Literature DB >> 17017514

Pathology associated with sporadic Parkinson's disease--where does it end?

H Braak1, C M Müller, U Rüb, H Ackermann, H Bratzke, R A I de Vos, K Del Tredici.   

Abstract

Parkinson's disease (PD) is a multisystem disorder in which predisposed neuronal types in specific regions of the human peripheral, enteric, and central nervous systems become progressively involved. A staging procedure for the PD-related inclusion body pathology (i.e., Lewy neurites and Lewy bodies) in the brain proposes that the pathological process begins at two sites and progresses in a topographically predictable sequence in 6 stages. During stages 1-2, the inclusion body pathology remains confined to the medulla oblongata, pontine tegmentum, and anterior olfactory structures. In stages 3-4, the basal mid- and forebrain become the focus of the pathology and the illness reaches its symptomatic phase. In the final stages 5-6, the pathological process is seen in the association areas and primary fields of the neocortex. To date, we have staged a total of 301 autopsy cases, including 106 cases with incidental pathology and 176 clinically diagnosed PD cases. In addition, 163 age-matched controls were examined. 19 of the 301 cases with PD-related pathology displayed a pathological distribution pattern of Lewy neurites and Lewy bodies that diverged from the staging scheme described above. In these cases, olfactory structures and the amygdala were predominantly involved in the virtual absence of brain stem pathology. Most of the divergent cases (17/19) had advanced concomitant Alzheimer's disease-related neurofibrillary changes (stages IV-VI).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17017514     DOI: 10.1007/978-3-211-45295-0_15

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  52 in total

1.  An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology.

Authors:  Christian Wider; Owen A Ross; Kenya Nishioka; Michael G Heckman; Carles Vilariño-Güell; Barbara Jasinska-Myga; Nilufer Erketin-Taner; Rosa Rademakers; Neill R Graff-Radford; Deborah C Mash; Spiridon Papapetropoulos; Ranjan Duara; Hirotake Uchikado; Zbigniew K Wszolek; Matthew J Farrer; Dennis W Dickson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-01-30       Impact factor: 10.154

Review 2.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

3.  Investigation of autonomic function in idiopathic REM sleep behavior disorder.

Authors:  Birgit Frauscher; Takashi Nomura; Susanne Duerr; Laura Ehrmann; Viola Gschliesser; Gregor K Wenning; Elisabeth Wolf; Yuichi Inoue; Birgit Högl; Werner Poewe
Journal:  J Neurol       Date:  2011-11-08       Impact factor: 4.849

Review 4.  Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself?

Authors:  Jeffrey H Kordower; C Warren Olanow
Journal:  Exp Neurol       Date:  2007-08-22       Impact factor: 5.330

5.  Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies.

Authors:  Lih-Fen Lue; Douglas G Walker; Charles H Adler; Holly Shill; Hung Tran; Haruhiko Akiyama; Lucia I Sue; John Caviness; Marwan N Sabbagh; Thomas G Beach
Journal:  Brain Pathol       Date:  2012-04-12       Impact factor: 6.508

6.  Time course of degeneration of dopaminergic neurons and respective compensatory processes in the nigrostriatal system in mice.

Authors:  A A Kolacheva; E A Kozina; E V Volina; M V Ugryumov
Journal:  Dokl Biol Sci       Date:  2014-07-02

7.  Basal ganglia and kinematics modulation: insights from Parkinson's and Huntington's diseases.

Authors:  Clara Moisello; Bernardo Perfetti; Lucio Marinelli; Vittorio Sanguineti; Marco Bove; Andrew Feigin; Alessandro Di Rocco; David Eidelberg; M F Ghilardi
Journal:  Parkinsonism Relat Disord       Date:  2011-07-20       Impact factor: 4.891

Review 8.  Staging neurodegenerative disorders: structural, regional, biomarker, and functional progressions.

Authors:  Trevor Archer; Richard M Kostrzewa; Richard J Beninger; Tomas Palomo
Journal:  Neurotox Res       Date:  2011-02       Impact factor: 3.911

9.  A preliminary diffusional kurtosis imaging study of Parkinson disease: comparison with conventional diffusion tensor imaging.

Authors:  Koji Kamagata; Hiroyuki Tomiyama; Taku Hatano; Yumiko Motoi; Osamu Abe; Keigo Shimoji; Kouhei Kamiya; Michimasa Suzuki; Masaaki Hori; Mariko Yoshida; Nobutaka Hattori; Shigeki Aoki
Journal:  Neuroradiology       Date:  2014-01-28       Impact factor: 2.804

10.  A cross-study transcriptional analysis of Parkinson's disease.

Authors:  Greg T Sutherland; Nicholas A Matigian; Alistair M Chalk; Matthew J Anderson; Peter A Silburn; Alan Mackay-Sim; Christine A Wells; George D Mellick
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.